Home Add to Favorite Contact Submit  
           23 September, 2019


    
Category:  Press » Health & Fitness

 

Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis

Popularity:
         Views: 1114
2008-07-09 09:19:20     
Cerimon Pharmaceuticals, Inc.

Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectious uveitis.

About Noninfectious Uveitis

Uveitis is an inflammation of the internal structures of the eye. Uveitis can be described by the underlying condition that causes it: autoimmune (noninfectious), bacterial, viral, parasitic and eye trauma, and by the part of the eye that it affects: anterior, intermediate, posterior and panuveitis. Noninfectious uveitis affects approximately two hundred forty thousand people worldwide and can lead to complications, such as glaucoma, cataract and total vision loss. Current treatments include topical and oral corticosteroids, steroidal implants and immunosuppressive drugs; however, these generally have limited success and can lead to adverse events.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians to further improve the lives of their patients.

Cerimon currently has two drugs in clinical development. The Company's autoimmune program has two development programs. The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for noninfectious uveitis in a Phase II study. Cerimon's lead asset in its pain portfolio is the Company's topical formulations of diclofenac. The Company is in mid-stage clinical testing with its topical diclofenac products.

The Company continues to seek additional assets to add to its development pipeline and is financed by the premier investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com .

Specialized in: Cerimon Pharmaceuticals - Ii Study - Evaluate Simulect
URL: http://www.cerimon.com
Print press release      Bookmark this page
Related Press releases 
The launch of Meddco Android App with new features to make healthcare affordable (Popularity: ): MUMBAI, India, 20 JULY, 2019 -​​​ Meddco.com® is pleased to announce the reintroduction of its Android and iOS Mobile App and its latest functionality which aims to improve the health of everyday people. The addition of new features made to the Android and iOS app will help patients compare the prices of different healthcare services and choose the most suitable one with a single click. Moreover, it includes dynamic pricing, ...
Bethesda MD In-Home Care Agency Educates Readers On Mental Exercises (Popularity: ): Rockville, Maryland ( press.abc-directory.com ) January 22, 2019 - Comfort Home Care, a Bethesda Maryland in-home care agency, released a guide for people with elderly loved ones outlining mental exercises for strengthening memory and cognition. The Maryland in-home care agency recommends that family members help elderly loved ones incorporate these exercises into their regular routines to promote better mental health.As our loved ones age, their mental abilities often decline. Reduced ...
Tooth Implant Sydney Now Announces to Use "Australian Approved" Dental Implant Brands (Popularity: ): Sydney, New South Wales ( press.abc-directory.com ) November 08, 2018 - Dental implants are one of the best tooth replacement solutions available in dentistry today, and offer significant health and aesthetic benefits. Choosing to receive dental implants will not only help to restore the function of mouth, but provides great improvements in oral health and quality of life. Understanding the importance of high quality dental implants at the lowest possible ...
Tooth Implant Sydney Now Announces to Offer High Quality and Affordable Dental Implant (Popularity: ): Sydney, New South Wales ( press.abc-directory.com ) March 26, 2018 - Having missing teeth is not only embarrassing but the mouth will deteriorate rapidly if left untreated. Dental implants help you look and feel better, regain your self-esteem, and have a better quality of life. Understanding the importance of dental implants and to help edentulous patients to get high quality and affordable dental implants, Tooth Implant Sydney now proudly offers ...
Kansas City Urology Care Launches Patient Portal for Easy Access to Medical Information (Popularity: ): Overland Park, Kansas ( press.abc-directory.com ) July 01, 2017 - Kansas City Urology Care launches online patient portal to facilitate easy access to medical information. The portal will be accessible via the service's official website 24 hours a day, 7 days a week. This is in accordance to the company's commitment to provide high quality treatment and care for all their patients.Patients who wish to set up an account shall ...

Press release home snapshot 


Related Business 
Uveitis and Iritis (Popularity: ): Website of Uveitis and Immunology Service at Massachusetts Eye and Ear Infirmary. It contains information about uveitis and iritis for patients and clinicians
Phase Converters from Tri-Phase Industries - Setting the Industry Standard (Popularity: ): Manufacturers and suppliers of phase converters for running 3-phase equipment on single phase power. Remanufactured and new static and rotary phase converters.
Superior Phase Converters (Popularity: ): Single Phase into 220V/440V 3-Phase Power. specialize in CNC, 3-Phase Farm Equipment, EDM, Woodworking.
Phase Technologies (Popularity: ): digital phase converters produce three-phase power from a single-phase source with voltages balanced within 1%, unity power factor and <2% harmonic distortion.
JD Machines (Popularity: ): Rotary phase converters run three-phase equipment on existing 220V single-phase power.
Kay Industries (Popularity: ): Manufacturer of Phasemaster single phase to three phase, phase converters.
EuroTech Machinery Ltd. (Popularity: ): New Zealand. Manufacturer of electronic phase converters - single phase to three phase. Importer of tooling and combination woodworking machines from Felder and Hammer.
Taylor Electronics, Inc. (Popularity: ): Manufactures a phase-balance voltage monitoring device used to prevent 3 phase motors and other equipment from operating or attempting to start up with one dead phase.
Medimpex UK, Ltd. (Popularity: ): A joint venture of two of the leading pharmaceutical companies in Eastern Europe: Egis Pharmaceuticals and Gedeon Richter. The company markets finished and bulk pharmaceuticals, feed additives and veterinary pharmaceuticals.
DES Electric (Popularity: ): phase converters, new, used and rebuilt rotary converter or static converters to run three phase motors on single phase.